Premium
A Pilot Study to Evaluate the Effectiveness of Glargine and Multiple Injections of Lispro in Patients With Type 2 Diabetes Receiving Tube Feedings in a Cardiovascular Intensive Care Unit
Author(s) -
Grainger Angela,
Eiden Kelly,
Kemper Judy,
Reeds Dominic
Publication year - 2007
Publication title -
nutrition in clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.725
H-Index - 71
eISSN - 1941-2452
pISSN - 0884-5336
DOI - 10.1177/0115426507022005545
Subject(s) - medicine , glycemic , diabetes mellitus , insulin lispro , retrospective cohort study , type 2 diabetes , insulin , type 2 diabetes mellitus , surgery , endocrinology
Background: The purpose of this study was to evaluate the effectiveness of insulin lispro and insulin glargine at controlling blood glucose in patients with type 2 diabetes mellitus in a cardiovascular intensive care unit (CICU) and receiving enteral tube feedings. Methods: This was a pilot study with a retrospective control designed to evaluate an insulin protocol in patients admitted to the CICU in a level 3 teaching institution. Patients were 18–99 years of age with type 2 diabetes mellitus, receiving bolus tube feeding. The control group included 24 patients who were retrospectively studied to determine mean blood glucose level. A glycemic management protocol was developed that included glargine and lispro insulins to maintain blood glucose levels between 80 and 140 mg/dL. The study group consisted of 28 patients who were treated according to the glycemic management protocol. Results: The mean blood glucose level of the retrospective control group was 225 mg/dL. The mean blood glucose level of the intervention group was 148 mg/dL. After protocol institution, 48.6% of blood glucose levels were within the goal blood glucose range of 80–140 mg/dL vs 8.26% ( p = .01) before protocol institution. Hyperglycemia decreased from 90.0% to 47.2% ( p < .0001) with institution of the protocol. Conclusions: The average blood glucose of the intervention group was slightly above the goal blood glucose range of 80–140 mg/dL; however, the study protocol was superior to the previous CICU blood glucose management protocol.